Global pharmaceutical manufacturer Lonza is expanding its production facilities in Pearland, Texas. Work began in March of 2016 on a 100,000-sf clinical manufacturing center, which will begin operations in late 2017. A second phase of construction will begin in fall of 2016 at the site, providing an additional 150,000 sf of office, laboratory, and manufacturing space.
GE Healthcare is planning to create a $167 million biopharmaceutical manufacturing campus in Ringaskiddy, Ireland. Featuring GE's prefabricated KUBio™ facilities, GE BioPark Cork will include four KUBio factories owned by independent biopharma companies. GE will manage the campus as well as providing centralized shared utilities and site services. Construction is expected to begin in mid-2017.
AstraZeneca is building the £750 million Global R&D Centre and Corporate Headquarters on the Cambridge Biomedical Campus in the United Kingdom. Providing advanced facilities for pharmaceutical discovery and development, the 580,000-sf project will include space for biologics research, high throughput screening, medicinal chemistry, pre-clinical research, and clinical studies. Designed to optimize interaction and connectivity, the collaborative 11-acre campus will accommodate approximately 2,000 employees and will include an on-site energy center.
Pfizer broke ground in June of 2016 on a $200 million clinical manufacturing facility for complex biologics and vaccines in Andover, Mass. The five-story, 175,000-sf facility is expected to be fully operational by January of 2019 and will accommodate 75 employees. Designed for maximum flexibility, the project will feature five independent production suites that utilize next-generation manufacturing strategies including single-use bioreactors and disposable process technologies.
JHL Biotech opened a biopharmaceutical manufacturing facility in May of 2016 in Wuhan, China. Featuring single-use bioprocessing technologies, the cGMP facility utilizes GE Healthcare's prefabricated KUBio system to produce biosimilars and monoclonal antibodies for late–stage clinical trials and commercial supply. The project was completed in just 18 months.
Fujifilm Diosynth Biotechnologies opened a 62,000-sf biopharmaceutical manufacturing facility in May of 2016 in Morrisville, N.C. Accommodating collaborative research and development, the three-story BioProcess Innovation Center supports the creation and production of advanced proteins, vaccines, and monoclonal antibodies. The project team included Alexandria Real Estate Equities and KBR Building Group. Ground was broken on the project in January of 2015.
Valent BioSciences is planning to construct the Biorational Research Center at Innovation Park in Libertyville, Ill. Enabling the consolidation of the company's chemistry, biology, microbiology, fermentation, and formulations labs in a single location, the $22 million project includes the buildout of 65,000 sf to create labs and offices as well as the construction of a 10,000-sf research greenhouse. Completion is expected in mid-2017. Valent BioSciences is a subsidiary of Sumitomo Chemical Company.
Shire Pharmaceuticals will begin construction in mid-2016 on a new biologics manufacturing campus in Piercetown, Ireland. Sited on 120 acres in County Meath, the project is part of Shire's $400 million investment over four years to expand its biopharmaceutical production capacity. The facility will utilize advanced bioprocessing technologies and will accommodate over 400 employees. Operations will commence at the site in mid-2019.
Global pharmaceutical manufacturer Lonza began construction in April of 2016 on a 100,000-sf facility in Pearland, Texas. Featuring a fully segregated fill/finish suite, the project will include eight independent cGMP modular cleanrooms with single-use bioreactors for the production of viral gene and virally modified therapeutics. Grade-B cleanrooms will also be constructed to continue the manufacture of EMA-regulated cell therapy products. Operations are expected to begin at the site in mid-2017.
Green Cross Biotherapeutics began building a $256 million biopharmaceutical manufacturing facility in Canada in June of 2015. Located on the Montreal Technoparc's Saint-Laurent Campus, the project will support the production of intravenous immunoglobulin (IVIG) and albumin products, and will act as the company's North American headquarters. The 225,000-gsf facility is expected to be fully operational in 2019 and will accommodate 200 scientists, engineers, and support staff. Green Cross Biotherapeutics is headquartered Yongin, South Korea.
Alexion Pharmaceuticals is planning to build a $515 million biologics manufacturing facility in Dublin. The 215,000-sf building will be located on the College Park campus in Blanchardstown and completion is expected in 2019. Alexion's global supply chain headquarters will also become operational at the site by year-end 2015.
WuXi Biologics began building a $150 million mammalian cell culture manufacturing facility in April of 2015 in Wuxi, China. Designed to utilize disposable bioreactors, the biopharmaceutical production plant will be the largest of its kind in the world and will be able to run continuous or semi-continuous manufacturing processes in addition to traditional modes. Completion is expected by January of 2017. WuXi Biologics is a wholly owned subsidiary of WuXi PharmaTech.
Nanotherapeutics is building the $135 million Advanced Development and Manufacturing Center in Alachua, Fla. Designed by RS&H, the 165,000-sf project will support vaccine development and production utilizing advanced biomanufacturing technologies. Ground was broken on the facility in October of 2013 and completion is expected by 2016. Nanotherapeutics is contracted to the Department of Defense to develop medical countermeasures to chemical and biological threats as well as infectious disease outbreaks.
Fujifilm Diosynth Biotechnologies broke ground in January of 2015 on a 62,000-sf biopharmaceutical manufacturing facility in Research Triangle Park, N.C. Designed to support collaborative research and development, the three-story BioProcess Innovation Center will accommodate the creation and production of advanced proteins, vaccines, and monoclonal antibodies. The project team includes Alexandria Real Estate Equities and KBR Building Group. Completion is expected in late 2015.
Stelis Biopharma has selected Bio-XCell to construct a $60 million biopharmaceutical manufacturing facility in Nusajaya in the Johor region of Malaysia. Providing mammalian and microbial production suites, the 140,000-sf project will feature next-generation, single-use bioprocessing technologies. Completion is expected in late 2016 with operations commencing in mid-2017. Stelis Biopharma is a wholly-owned subsidiary of Strides Arcolab.
